Sun Pharmaceutical Industries: 7 Stock Signals Investors Are Watching Right Now
- September 17, 2026
- Posted by: Harsh Piplani
- Category: Market
Sun Pharmaceutical Industries CMP Rs 1,860.5. 52W range Rs 1,548-2,047. Mcap Rs 4.45 lakh crore. PE 36.7 vs sector 37.4.
Quick Answer
Sun Pharma stock signals right now span an earnings picture, a shareholding pattern where promoter holding has been unchanged at 54.48% for five straight quarters, and a technical setup where the stock trades well off its 52-week low of Rs 1,548. Debt to equity stands at 0.06, and valuation sits at a P/E of 36.7 against a sector average of 37.4. Corporate developments in the pharmaceuticals, India’s largest drugmaker by market capitalisation space add further context investors are tracking alongside these numbers. None of the seven signals here amounts to a buy or sell call on its own.
Sun Pharma stock signals are unusually layered right now, with the company trading at Rs 1,860.5, 9.1% below its 52-week high of Rs 2,047 and 20.2% above its 52-week low of Rs 1,548. Sun Pharmaceutical Industries is a well tracked name in the pharmaceuticals, India’s largest drugmaker by market capitalisation space, and no single headline captures where the stock stands today.
This article does not make a buy, hold or sell call on Sun Pharmaceutical Industries. It lays out seven signals investors commonly watch, each sourced from the company’s latest exchange disclosures and financial statements, so readers can form their own view of what is currently working for the stock and what still needs to be watched.
Click Here – Get Free Investment Predictions
Sun Pharmaceutical Industries Stock at a Glance
Before going through each of the seven Sun Pharma stock signals in detail, the snapshot below sets the starting point on price, valuation and balance sheet strength.
| Metric | Value |
|---|---|
| Sun Pharmaceutical Industries CMP | Rs 1,860.5 (NSE, 17 Sep 2026) |
| 52-Week High | Rs 2,047 (27 July 2026) |
| 52-Week Low | Rs 1,548 (22 September 2025) |
| Market Capitalisation | Rs 4.45 lakh crore |
| P/E Ratio | 36.7 (Sector P/E 37.4) |
| P/B Ratio | 5.32 |
| Debt to Equity | 0.06 |
| Return on Equity | 13.74% |
1. Earnings Trend at Sun Pharmaceutical Industries
Sun Pharmaceutical Industries closed the latest full year with revenue of Rs 61,674 crore versus Rs 54,729 crore a year earlier, while net profit moved to Rs 11,565 crore from Rs 10,980 crore, a change of 5.3% on the year. The most recent quarter added Rs 16,024 crore in revenue, a change of 11.9% year on year, against Rs 2,911 crore in net profit versus Rs 2,303 crore a year earlier.
operating margin has ranged between 28.6% and 34.7% over the last five quarters; full year FY26 net profit grew a modest 5.3%, and analysts flagged an EPS miss of about 22% in a recent quarter even as the June 2026 quarter itself showed solid year on year growth. This is the first of the seven Sun Pharma stock signals worth tracking closely into the next results.
2. FII Holding in Sun Pharmaceutical Industries
FII holding in Sun Pharmaceutical Industries has declined from 17.26% to 14.53% across the last reported quarters (Jun ’25 17.26%, Sep ’25 16.55%, Dec ’25 16.12%, Mar ’26 15.93%, Jun ’26 14.53%). Domestic institutions have moved from 19.5% to 22.18% over the same stretch.
Reading FII and DII holding together alongside the price action gives a fuller picture than either figure alone, since foreign and domestic flows do not always move in the same direction around a stock’s price swings.
3. Promoter Holding in Sun Pharmaceutical Industries
Promoter holding in Sun Pharmaceutical Industries has been unchanged at 54.48% for five straight quarters, based on the last reported quarters (Jun ’25 54.48%, Sep ’25 54.48%, Dec ’25 54.48%, Mar ’26 54.48%, Jun ’26 54.48%).
A stable or rising promoter stake is typically read as a sign that controlling shareholders have not used any recent price weakness to pare their position, though it is only one data point among the seven here.
4. Debt Position at Sun Pharmaceutical Industries
Sun Pharmaceutical Industries’s debt to equity ratio stands at 0.06, versus 0.04 in FY25 a year earlier, one of the balance sheet metrics worth tracking alongside the earnings trend above. A lower or stable ratio generally gives more room to fund growth without leaning further on external borrowing, while a rising one is worth watching for its effect on finance costs.
This debt signal should be read alongside the valuation and corporate development signals below rather than in isolation, since capital raising plans can shift the picture from one quarter to the next.
5. Valuation of Sun Pharmaceutical Industries Shares
At the current price, Sun Pharmaceutical Industries trades at a price to earnings ratio of 36.7, a discount of close to 1.9% versus the sector average of 37.4. The price to book ratio stands at 5.32.
Whether that discount looks justified depends on the earnings trend from Signal 1 continuing, and it is one of the clearer places where the seven signals can pull in different directions at the same time.
6. Technical Trend on the Sun Pharmaceutical Industries Chart
The stock closed around Rs 1,860.5, positioned between its 50-day moving average of about Rs 1,926 and its 200-day moving average of about Rs 1,806, a mixed technical picture. The 14-day RSI reads close to 40, in neutral territory. The MACD line sits below its signal line, a bearish momentum bias on the daily chart.
Over the past year the stock is currently 9.1% below its 52-week high of Rs 2,047 and 20.2% above its 52-week low of Rs 1,548. A sustained move back above the 50-day average would be an early technical sign of stabilisation.
7. Corporate Developments at Sun Pharmaceutical Industries
Sun Pharmaceutical Industries missed analyst EPS estimates by roughly 22% in a recent quarter, according to brokerage commentary, and the board separately declared a dividend of Rs 5.50 per share in June 2026, even as the stock has held up better than several peers hit by pricing pressure in the US generics market this year.
Check the Univest Screener for live fundamentals
What These Sun Pharma stock signals Mean Together
None of these seven signals on its own settles the debate on Sun Pharmaceutical Industries. Reading them as a set, rather than picking out any single one, is the more balanced way to approach the stock right now. The earnings trend, shareholding pattern, balance sheet position, valuation, technical setup and corporate developments each add one piece of the picture, and they do not all point the same way at the same time.
Investors weighing Sun Pharmaceutical Industries would do well to watch the next quarterly results for a read on where margins and profit are heading, alongside the next shareholding pattern update for any shift in FII or promoter positioning. Reading these Sun Pharma stock signals together, rather than in isolation, remains the more balanced approach. As with any single stock, price movements can be volatile and past trends do not guarantee future performance.
Also Read: HDFC Bank: 7 Stock Signals Investors Are Watching Right Now
Conclusion
Sun Pharmaceutical Industries currently sits at the intersection of several moving parts, from earnings and shareholding to valuation and chart trend, and that is exactly what the seven signals above are meant to surface. This article does not recommend buying, holding or selling Sun Pharmaceutical Industries shares, and readers should form their own view based on their own research and risk appetite.
Download the Univest iOS App or Univest Android App to track Sun Pharmaceutical Industries live price and more such signal based stock research.
Disclaimer: Data and figures in this article are sourced from publicly available information and the company’s exchange filings. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Sun Pharmaceutical Industries Stock Signals
Why is Sun Pharmaceutical Industries share price where it is right now?
Ans. Sun Pharmaceutical Industries shares are trading 9.1% below their 52-week high of Rs 2,047 and 20.2% above their 52-week low of Rs 1,548, shaped by the earnings trend, shareholding shifts and technical setup covered in this article, rather than any single factor.
What is Sun Pharmaceutical Industries’s current FII holding?
Ans. FII holding in Sun Pharmaceutical Industries stood at 14.53% as of the most recent quarter.
Is Sun Pharmaceutical Industries’s debt position a concern right now?
Ans. The debt to equity ratio stands at 0.06, versus 0.04 in FY25 a year earlier.
What is the promoter holding in Sun Pharmaceutical Industries?
Ans. Promoter holding in Sun Pharmaceutical Industries stood at 54.48% as of the most recent quarter.
Is Sun Pharmaceutical Industries expensive compared to its sector?
Ans. Sun Pharmaceutical Industries trades at a price to earnings ratio of 36.7 against a sector average of 37.4.
What recent corporate developments are relevant to Sun Pharmaceutical Industries?
Ans. Sun Pharmaceutical Industries missed analyst EPS estimates by roughly 22% in a recent quarter, according to brokerage commentary, and the board separately declared a dividend of Rs 5.50 per share in June 2026, even as the stock has held up better than several peers hit by pricing pressure in the US generics market this year.
What do the technical charts suggest about Sun Pharmaceutical Industries right now?
Ans. The stock is trading positioned between its 50-day moving average of about Rs 1,926 and its 200-day moving average of about Rs 1,806, a mixed technical picture, with a 14-day RSI near 40 and its MACD line below its signal line, a bearish momentum bias.
Should investors buy Sun Pharmaceutical Industries shares at current levels?
Ans. This article does not offer a buy, hold or sell recommendation. It lays out seven Sun Pharma stock signals, earnings, FII holding, promoter holding, debt, valuation, technicals and corporate developments, so investors can weigh each signal and form their own view based on their goals and risk appetite.
